EFFECTOR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 USD | -4.28% |
|
-10.50% | -84.68% |
| May. 09 | EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 04 | Health Care Down on Retreat From Risk -- Health Care Roundup | DJ |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 334.3 | 17.91 | 30.2 | 8.421 | - | - |
| Enterprise Value (EV) 1 | 304.4 | 11.76 | 30.2 | -9.579 | -42.58 | 8.421 |
| P/E ratio | 18.8 x | -0.78 x | -0.71 x | -0.29 x | -0.8 x | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 234 x | 5.04 x | - | - | - | - |
| EV / Revenue | 213 x | 3.31 x | - | - | - | - |
| EV / EBITDA | -9,551,529 x | -363,663 x | - | - | - | - |
| EV / FCF | -12.2 x | -0.45 x | - | 0.27 x | 1.12 x | -0.2 x |
| FCF Yield | -8.19% | -222% | - | 365% | 89.2% | -499% |
| Price to Book | 7.24 x | -0.12 x | - | - | - | - |
| Nbr of stocks (in thousands) | 1,615 | 1,676 | 2,585 | 4,704 | - | - |
| Reference price 2 | 207.0 | 10.69 | 11.68 | 1.790 | 1.790 | 1.790 |
| Announcement Date | 3/16/22 | 3/8/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.43 | 3.553 | - | - | - | - |
| EBITDA | - | -31.87 | -32.35 | - | - | - | - |
| EBIT 1 | - | -31.9 | -32.4 | -33.84 | -32.8 | -35.5 | - |
| Operating Margin | - | -2,230.56% | -911.99% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | 15.8 | -22.66 | -35.81 | -34.6 | -37.1 | - |
| Net income 1 | 0.166 | 15.8 | -22.66 | -35.81 | -34.6 | -37.1 | - |
| Net margin | - | 1,104.76% | -637.91% | - | - | - | - |
| EPS 2 | 0.2500 | 11.00 | -13.75 | -16.37 | -6.170 | -2.250 | - |
| Free Cash Flow 1 | - | -24.93 | -26.09 | - | -35 | -38 | -42 |
| FCF margin | - | -1,743.36% | -734.34% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 6/14/21 | 3/16/22 | 3/8/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.311 | - | 2.011 | 0.867 | 0.674 | - | - | - | - | - | - | - | - |
| EBITDA | -12.4 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -12.4 | -6.548 | -7.881 | -9.251 | -8.723 | -9.536 | -7.855 | -7.855 | -8.598 | -8.396 | -8.4 | -8.2 | -7.8 |
| Operating Margin | -3,988.1% | - | -391.89% | -1,067.01% | -1,294.21% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 19.05 | 3.069 | -6.915 | -9.559 | -9.261 | -10.01 | -8.364 | -8.303 | -9.13 | -8.834 | -8.8 | -8.7 | -8.3 |
| Net income 1 | 19.05 | 3.069 | -6.915 | -9.559 | -9.261 | -10.01 | -8.364 | -8.303 | -9.13 | -8.834 | -8.8 | -8.7 | -8.3 |
| Net margin | 6,125.08% | - | -343.86% | -1,102.54% | -1,374.04% | - | - | - | - | - | - | - | - |
| EPS 2 | 11.00 | 1.750 | -4.250 | -5.750 | -5.500 | -6.000 | -4.250 | -3.250 | -3.420 | -2.160 | -2.020 | -1.950 | -0.8700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/22 | 5/10/22 | 8/9/22 | 11/7/22 | 3/8/23 | 5/9/23 | 8/8/23 | 11/13/23 | 3/26/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 29.8 | 6.15 | - | 18 | 51 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -24.9 | -26.1 | - | -35 | -38 | -42 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | 28.60 | -87.30 | - | - | - | - |
| Cash Flow per Share | - | -17.30 | -15.70 | - | - | - | - |
| Capex 1 | - | 0.04 | 0.19 | - | - | 10 | 15 |
| Capex / Sales | - | 2.94% | 5.4% | - | - | - | - |
| Announcement Date | 6/14/21 | 3/16/22 | 3/8/23 | 3/26/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.79
USD
Average target price
11
USD
Spread / Average Target
+514.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -84.68% | 8.8M | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- EFTR Stock
- Financials eFFECTOR Therapeutics, Inc.